Table 1.
Baseline characteristics of overweight/obese patients with PCOS.
| Variables | Dulaglutide Combined with CRD Therapy (n = 35) |
CRD Therapy (n = 33) |
|---|---|---|
| Age (years) | 30.31 (28.58 to 32.05) | 28.64 (27.09 to 30.18) |
| Weight (kg) | 77.62 (74.19 to 81.06) | 78.84 (74.24 to 83.43) |
| WC (cm) | 96.76 (93.61 to 99.92) | 94.89 (91.45 to 98.33) |
| BMI (kg/m2) | 29.68 (28.44 to 30.93) | 29.71 (28.39 to 31.04) |
| Menstrual Cycles (no./yr) | 7.44 (6.07 to 8.81) | 7.90 (6.83 to 8.96) |
| SBP (mmHg) | 124.14 (119.77 to 128.52) | 127.69 (121.16 to 134.22) |
| DBP (mmHg) | 82.06 (78.55 to 85.56) | 84.38 (79.81 to 88.94) |
| FPG (mmol/L) | 4.96 (4.77 to 5.14) | 5.03 (4.85 to 5.21) |
| PPG (mmol/L) | 7.53 (6.57 to 8.50) | 7.58 (6.81 to 8.34) |
| FINS (mU/L) | 21.54 (17.19 to 25.89) | 22.59 (14.44 to 30.75) |
| PINS (mU/L) | 139.41 (99.15 to 179.67) | 149.16 (111.19 to 187.14) |
| HbA1c (%) | 5.72 (5.61 to 5.84) | 5.64 (5.48 to 5.80) |
| HOMA-IR | 4.85 (3.79 to 5.91) | 5.18 (3.26 to 7.10) |
| ALT (U/L) | 47.99 (35.45 to 60.52) | 35.06 (27.58 to 42.54) |
| AST (U/L) | 27.91 (22.83 to 33.00) | 22.08 (18.48 to 25.68) |
| TC (mmol/L) | 4.81 (4.49 to 5.13) | 4.74 (4.46 to 5.02) |
| TG (mmol/L) | 1.64 (1.34 to 1.94) | 1.64 (1.36 to 1.93) |
| LDL-c (mmol/L) | 3.10 (2.77 to 3.44) | 3.04 (2.76 to 3.32) |
| HDL-c (mmol/L) | 1.28 (1.21 to 1.35) | 1.31 (1.22 to 1.41) |
| Cr (umol/L) | 62.06 (60.24 to 63.88) | 60.94 (58.68 to 63.19) |
| SUA (umol/L) | 396.27 (371.54 to 421.00) | 372.60 (340.88 to 404.32) |
| LH (IU/L) | 9.06 (7.34 to 10.79) | 11.62 (9.73 to 13.50) |
| FSH (IU/L) | 5.45 (4.69 to 6.20) | 5.54 (5.08 to 5.99) |
| PRL (mIU/L) | 379.84 (322.33 to 437.36) | 356.00 (304.60 to 407.39) |
| TT (nmol/L) | 1.76 (1.48 to 2.04) | 1.84 (1.60 to 2.07) |
| FT (pg/mL) | 2.53 (2.13 to 2.93) | 2.40 (1.99 to 2.81) |
| AD (ng/mL) | 4.16 (3.55 to 4.77) | 4.61 (3.46 to 5.76) |
| DHEAS (ug/dl) | 227.83 (193.64 to 262.02) | 225.00 (182.71 to 267.29) |
| SHBG (nmol/L) | 29.74 (16.80 to 42.67) | 23.96 (14.59 to 33.33) |
| FAI | 0.09 (0.07 to 0.11) | 0.11 (0.08 to 0.13) |
| CAP (dB/m) | 332.69 (314.13 to 351.25) | 318.70 (300.50 to 336.89) |
| LSM (kPa) | 5.95 (5.29 to 6.61) | 5.82 (5.00 to 6.64) |
| Total body fat (%) | 43.27 (42.08 to 44.46) | 43.57 (42.25 to 44.89) |
| Total body lean (%) | 53.50 (52.37 to 54.64) | 52.75 (51.44 to 54.07) |
| Total fat mass (kg) | 33.03 (30.94 to 35.11) | 33.50 (31.20 to 35.80) |
| Total lean mass (kg) | 40.68 (39.13 to 42.23) | 40.29 (37.85 to 42.73) |
| VAT area (cm2) | 163.03 (146.19 to 179.88) | 156.74 (140.42 to 173.05) |
| SAT mass (kg) | 1.96 (1.79 to 2.13) | 1.92 (1.73 to 2.12) |
The data are presented as the mean (95% CI). AD, androstenedione; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; Cr, Creatinine; CRD, calorie-restricted diet; DBP, diastolic blood pressure; DHEAS, dehydroepiandrosterone sulfate; FAI, free androgen index; FINS, fasting insulin; FPG, fasting plasma glucose; FSH, follicle-stimulating hormone; FT, free testosterone; HbA1c, glycosylated hemoglobin A1c; HDL-c, high- density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-c, low-density lipoprotein cholesterol; LH, luteinizing hormone; LSM, liver stiffness measurement; PCOS, polycystic ovary syndrome; PINS, postprandial insulin; PPG, postprandial plasma glucose; PRL, pituitary prolactin; SAT, subcutaneous adipose tissue; SBP, systolic blood pressure; SHBG, sex hormone-binding globulin; SUA, serum uric acid; TC, total cholesterol; TG, triglyceride; TT, total testosterone; VAT, visceral adipose tissue; WC, waist circumference.